Research programme: peptide therapeutics - PhaseBio Pharmaceuticals

Drug Profile

Research programme: peptide therapeutics - PhaseBio Pharmaceuticals

Alternative Names: Insulin-ELP; PB 1120; VIP-ELP-120

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PhaseBio Pharmaceuticals
  • Class Biopolymers; Drug conjugates; Insulins; Pancreatic hormones; Peptide hormones; Recombinant fusion proteins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants; Vasoactive intestinal peptide receptor agonists; Vasoactive intestinal peptide type II receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis
  • No development reported Diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (SC)
  • 01 May 2016 Preclinical trials in Cystic fibrosis in USA (unspecified route)
  • 01 Jan 2012 Preclinical trials in Diabetes mellitus in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top